Skip to Content

Granix (tbo-filgrastim) Disease Interactions

There are 2 disease interactions with Granix (tbo-filgrastim):


Csf (Includes Granix) ↔ Glomerulonephritis

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis. Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production. Advise patients to report signs or symptoms of glomerulonephritis immediately. Monitoring of patients with renal dysfunction is recommended.


Tbo-Filgrastim (Includes Granix) ↔ Tumor Growth

Moderate Potential Hazard, Moderate plausibility

Applies to: Myelodysplastic Disease

Tbo-filgrastim can act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia disease, diseases for which its use has not been approved.

Granix (tbo-filgrastim) drug Interactions

There are 133 drug interactions with Granix (tbo-filgrastim)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.